Abstract

Objective: Increased levels of Angiotensin II (Ang II) are responsible for the development of hypertension and diabetes-induced nephropathy. In addition, the preventability of renal fibrosis with Ang II blockade is a known entity. Although mast cells are not present in normal kidney, increased mast cell density in the specimens examined for fibrosis has attracted attention and it is thought that fibrotic agents released from these cells and may contribute to the process. Therefore, an experimental study was planned to decrease the ang II levels with captopril, an angiotensin converting enzyme (ACE) inhibitor and to prevent the development of renal scarring due to pyelonephritis using ketotifen, a mast cell stabilizer.

Material and Methods: Fifty rats were divided into five equal groups. In Group A, the renal cortex was injected with SF. In Group B, acute pyelonephritis was induced by 107 E. coli injections into the renal cortex. Group C received antibiotic treatment with E. coli injection, Group D received antibiotic and captopril with E. coli injection, Group E. received antibiotic and ketotifen with E. coli injection. In order to represent the chronic process, rats were sacrificed after 6 weeks, and the contralateral kidney was included in pathological examination and statistical evaluation.

Results: Inflammatory scores were significantly higher in group B compared to group A (p = 0.001). Captopril or ketotifen treatment were the only factors that reduced scar development (p = 0.007). However, when captopril or ketotifen treatments were compared in preventing scar development, no superiority was found (p> 0.05).

Conclusion: We found that captopril and ketotifen has a protective effect in the development of renal fibrosis in a rat model of acute pyelonephritis. We believe that our study may contribute to clinical trials in the prevention of renal scar development.

Keywords: Angiotensin-converting enzyme inhibitors, Captopril, Ketotifen, Renal fibrosis

References

  1. Shortliffe LMD. Infection and Inflammation of Pediatric Genitourinary Tract. 10th Edition, In Philadelphia, Elsevier Saunders: Cambell-Walsh Urology, 2012.
  2. Lin R. Vesicoureteral reflux and urinary tract infection evolving practices and current controversies in pediatric imaging. AJR Am J Roentgenol. 2009;192:1197-1208
  3. Simões e Silva AC1, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013 Jun;169(3):477-92.
  4. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007 Sep;59(3):251-87.
  5. Youxia Liu , Xinxin Ma , Jie Zheng , Junya Jia and Tiekun Yan. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrology (2017) 18:206 DOI 10.1186/s12882-017-0605-7
  6. Lama G, Salsano M E, Pedulla M, Grassia C, Ruocco G. Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up. Pediatr. Nephrol(Berlin, Germany). - December 1, 1997; 11 (6); 714-8
  7. Kitao T, Kimata T, Yamanouchi S, Kato S, Tsuji S, Kaneko K. Urinary Biomarkers for Screening for Renal Scarring in Children with Febrile Urinary Tract Infection: Pilot Study. J Urol. 2015 Sep;194(3):766-71. doi: 10.1016/j.juro.2015.04.091. Epub 2015 Apr 29.
  8. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998 Sep;32(3):387-92.
  9. Yamada M, Ueda M, Naruko T, Tanabe S, Han YS, Ikura Y, Ogami M, Takai S, Miyazaki M. Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int. 2001 Apr;59(4):1374-81.
  10. Li Y, Liu FY, Peng YM, Li J, Chen J. Mast cell, a promising therapeutic target in tubulointerstitial fibrosis. Med Hypotheses. 2007;69(1):99-103. Epub 2007 Jan 25.
  11. Wu Y1, Liu Z, Hu W, Li L. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy. Hum Exp Toxicol. 2005 Feb;24(2):41-7.
  12. Dai H, Korthuis RJ. Mast Cell Proteases and Inflammation. Drug Discov Today Dis Models. 2011 Spring;8(1):47-55.
  13. Columbo M, Horowitz EM, Botana LM, McGlashan DW Jr, Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 1992;149: 599 –608.
  14. Kondo S, Kagami S, Kido H, Strutz F, Müller GA, Kuroda Y. Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol. 2001 Aug;12(8):1668-76.
  15. Singal AK, Bajpai M, Dinda AK. Blockade of Renin-Angiotensin system blunts the fibrotic response in experimental acute pyelonephritis. J Indian Assoc Pediatr Surg/ Jan-Mar 2005/vol 10/Issue 1:20-24
  16. Abareshi A, Norouzi F, Asgharzadeh F, Beheshti F, Hosseini M, Farzadnia M, Khazaei M. Effect of Angiotensin-converting Enzyme Inhibitor on Cardiac Fibrosis and Oxidative Stress Status in Lipopolysaccharide-induced Inflammation Model in Rats.Int J Prev Med. 2017 Sep 6;8:69. doi: 10.4103/ijpvm.IJPVM_322_16. eCollection 2017.
  17. Hrenák J, Arendášová K, Rajkovičová R, Aziriová S, Repová K, Krajčírovičová K, Celec P, Kamodyová N, Bárta A, Adamcová M, Paulis L, Simko F.Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats. Physiol Res. 2013;62 Suppl 1:S181-9.
  18. Kostan W Reisinger, Jacco J de Haan, and Marc H Schreinemacher. Word of caution before implementing ketotifen for gastrointestinal transit improvement. World J Gastroenterol. 2013 Jul 21; 19(27): 4445–4446. Published online 2013 Jul 21. doi: 10.3748/wjg.v19.i27.4445
  19. Yukselen V, Karaoglu AO, Ozutemiz O, Yenisey C, Tuncyurek M. Ketotifen ameliorates development of fibrosis in alkali burns of the esophagus. Pediatr Surg Int. 2004 Jun;20(6):429-33. Epub 2004 Apr 24.
  20. Emamghorashi F, Owji SM, Motamedifar M. Evaluation of Effectiveness of Vitamins C and E on Prevention of Renal Scar due to Pyelonephritis in Rat. Adv Urol. 2011; 2011:489496.
  21. Roupakias S, Sinopidis X, Karatza A, Varvarigou A. Predictive risk factors in childhood urinary tract infection, vesicoureteral reflux, and renal scarring management. Clin Pediatr (Phila). 2014 Oct;53(12):1119-33.
  22. Smith EA. Pyelonephritis, renal scarring, and reflux nephropathy: a pediatric urologist's perspective. Pediatr Radiol. 2008 Jan;38 Suppl 1:S76-82.
  23. Roberts IS, Brenchley PE. Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol. 2000 Nov;53(11):858-62.

Copyright and license

Copyright © 2019 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Azılı MN, Karakuş E, Şenaylı A, Tiryaki T. Effects of Captopril and Ketotifen on Protecting Against Renal Scarring Due to Pyelonephritis Injury. Turk J Pediatr Dis [Internet]. 2019 Dec. 23 [cited 2025 Aug. 23];13(6):475-80. Available from: https://turkjpediatrdis.org/article/view/560